335results about How to "Improve compound" patented technology

Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.

Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.

This invention discloses a method for preparing rubber compositions that exhibit unique combinations of properties that are desirable for tire tread applications for enhanced snow / ice and wet traction, low rolling resistance and increased treadwear performance in comparison with conventional silica compounds. Specifically, a high reactively silane coupling agent, such as a mercaptosilane, is used in combination with a silane coupling typically used for silica tread compounds such as bis(triethoxylsilylpropyl)disulfide to treat silica pellets in a hydrocarbon solvent at elevated temperatures. The treated silica is then blended with solution elastomer cement in a hydrocarbon solvent. The deposited reactive silanes partially react with the elastomer molecules forming a layer of polymer grafted on the silica surfaced. This structure significantly improves the silica retention during the steam stripping operation. Almost 100% (99+%) silica retention has been achieved by this invention. After solvent removal from steam stripping, the treated silica / elastomer mixer is dewatered and dried using conventional equipment such as shaker screens, expellers and expanders to form a well-dispersed silica masterbatch. This technique results in silica compounds with excellent silica dispersion and increased filler-polymer interaction, hence enhanced compound performance such as better physical properties, more desirable dynamic properties (low hysteresis at high temperatures and high hysteresis at low temperatures) and increased abrasion resistance.

The invention relates to bifunctional stapled or stitched peptides comprising a targeting domain, a linker moiety, and an effector domain, that can be used to tether, or to bring into close proximity, at least two cellular entities (e.g., proteins). Certain aspects relate to bifunctional stapled or stitched peptides that bind to an effector biomolecule through the effector domain and bind to a target biomolecule through the targeting domain. Polypeptides and / or polypeptide complexes that are tethered by the bifunctional stapled or stitched peptides of the invention, where the effector polypeptide bound to the effector domain of the bifunctional stapled or stitched peptide modifies or alters the target polypeptide bound to the targeting domain of the bifunctional peptide. Uses of the inventive bifunctional stapled or stitched peptides including methods for treatment of disease (e.g., cancer, inflammatory diseases) are also provided.

Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, and in some embodiments an improved half-life in circulation as compared to unmodified counterpart natriuretic compounds. Oral, parenteral, subcutaneous, and intravenous forms of the compounds and conjugates may be prepared as treatments and / or therapies for heart conditions particularly congestive heart failure. Modifying moieties comprising oligomeric structures having a variety of lengths and configurations are also disclosed. Analogs of the natriuretic compound are also disclosed, having an amino acid sequence that is other than the native sequence.